非清髓性TLI-ATG预处理异基因移植:单中心大样本成熟随访
该单中心回顾性研究纳入2001至2016年在斯坦福大学接受TLI-ATG非清髓预处理异基因移植的612例血液系统恶性肿瘤患者,中位随访6.0年。结果显示GVHD及非复发死亡率低,各病种均可获得持久缓解,尤其经重度治疗的淋巴瘤 outcomes 较好。混合嵌合与复发风险相关。
要点
- TLI-ATG预处理后1年II-IV级急性GVHD为14%,广泛型慢性GVHD为22%,非复发死亡为9%。
- 4年总生存/无进展生存:AML 42%/32%,MDS 30%/21%,CLL 67%/43%,NHL 68%/45%,HL 78%/49%。
核心结论
- TLI-ATG非清髓预处理耐受性好,GVHD和非复发死亡率低,在各血液恶性肿瘤中可获持久缓解,尤其对重度治疗淋巴瘤效果较好。
研究设计与样本
- 单中心回顾性队列,纳入2001至2016年斯坦福大学612例接受TLI-ATG预处理异基因移植的血液恶性肿瘤患者,中位年龄60岁,中位随访6.0年。
主要发现
- 1年非复发死亡率为9%,II-IV级急性GVHD为14%,广泛型慢性GVHD为22%。
- 4年总生存/无进展生存:AML 42%/32%,MDS 30%/21%,CLL 67%/43%,NHL 68%/45%,HL 78%/49%。
- 混合嵌合与复发风险相关。
关键数值与推荐
- 所有患者接受G-CSF动员的外周血移植物,采用环孢素联合吗替麦考酚酯预防GVHD。
临床怎么用
- TLI-ATG可作为血液恶性肿瘤患者非清髓异基因移植的预处理选择,尤其适合门诊移植及重度治疗淋巴瘤患者。
- 移植后需监测混合嵌合状态以评估复发风险。
局限性
- 单中心回顾性设计,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonmyeloablative total lymphoid irradiation and antithymocyte globulin (TLI-ATG) conditioning is protective against graft-versus-host disease (GVHD), while retaining graft-versus-tumor activity across various hematologic malignancies. We report our comprehensive experience using TLI-ATG conditioning in 612 patients with hematologic malignancies who underwent allogeneic transplantation at Stanford University from 2001 to 2016. All patients received granulocyte colony-stimulating factor-mobilized peripheral blood grafts and cyclosporine and mycophenolate mofetil for GVHD prophylaxis. The median age was 60 years (range, 21-78), with a median follow-up of 6.0 years (range, 1.0-16.4). Common diagnoses included acute myeloid leukemia (AML; n = 193), myelodysplastic syndrome (MDS; n = 94), chronic lymphocytic leukemia (CLL; n = 80), non-Hodgkin lymphoma (NHL; n = 175), and Hodgkin lymphoma (HL; n = 35). Thirty-four percent of patients had a comorbidity index ≥3, 30% had a high to very high disease risk index, and 56% received unrelated donor grafts, including 15% with HLA-mismatched donors. Ninety-eight percent underwent transplant in the outpatient setting, and 57% were never hospitalized from days 0 through 100. The 1-year rates of nonrelapse mortality (NRM), grade II-IV acute GVHD, and extensive chronic GVHD were 9%, 14%, and 22%, respectively. The 4-year estimates for overall and progression-free survival were 42% and 32% for AML, 30% and 21% for MDS, 67% and 43% for CLL, 68% and 45% for NHL, and 78% and 49% for HL. Mixed chimerism correlated with the risk of relapse. TLI-ATG conditioning was well tolerated, with low rates of GVHD and NRM. Durable remissions were observed across hematologic malignancies, with particularly favorable outcomes for heavily pretreated lymphomas. Several efforts are underway to augment donor chimerism and reduce relapse rates while maintaining the favorable safety and tolerability profile of this regimen.
引用
- Spinner MA, Kennedy VE, Tamaresis JS, et al. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Adv. 2019. PMID: 31427277. doi:10.1182/bloodadvances.2019000297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。